| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.010 | GeneticVariation | disease | BEFREE | This method was successfully applied to pharmacokinetic study of CGA in Chinese subjects with advanced solid tumor after intramuscular injection administration of Chlorogenic acid for injection (CAFI). | 31541942 | 2020 | ||||
|
0.010 | GeneticVariation | disease | BEFREE | Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. | 31118108 | 2019 | ||||
|
0.010 | Biomarker | disease | BEFREE | A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. | 30418178 | 2019 | ||||
|
0.010 | Biomarker | disease | BEFREE | Our results showed for the first time that simultaneous co-delivery of the NKT agonist α-galactosylceramide and tumor self-antigens (Trp2 and gp100) to CD8α<sup>+</sup> DCs promotes strong antitumor responses in prophylactic and therapeutic settings (advanced solid tumor model in the mouse). | 28932640 | 2017 | ||||
|
0.010 | Biomarker | disease | BEFREE | Our results showed for the first time that simultaneous co-delivery of the NKT agonist α-galactosylceramide and tumor self-antigens (Trp2 and gp100) to CD8α<sup>+</sup> DCs promotes strong antitumor responses in prophylactic and therapeutic settings (advanced solid tumor model in the mouse). | 28932640 | 2017 | ||||
|
0.010 | Biomarker | disease | BEFREE | Our results showed for the first time that simultaneous co-delivery of the NKT agonist α-galactosylceramide and tumor self-antigens (Trp2 and gp100) to CD8α<sup>+</sup> DCs promotes strong antitumor responses in prophylactic and therapeutic settings (advanced solid tumor model in the mouse). | 28932640 | 2017 | ||||
|
0.010 | Biomarker | disease | BEFREE | Our results showed for the first time that simultaneous co-delivery of the NKT agonist α-galactosylceramide and tumor self-antigens (Trp2 and gp100) to CD8α<sup>+</sup> DCs promotes strong antitumor responses in prophylactic and therapeutic settings (advanced solid tumor model in the mouse). | 28932640 | 2017 | ||||
|
0.010 | Biomarker | disease | BEFREE | A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. | 19092859 | 2009 |